8-K filed Feb 24, 2026 at 16:10 ET
Corcept Therapeutics reported full-year 2025 revenue of $761.4 million, a 12.8% increase from 2024, driven by strong demand in its Cushing's syndrome business despite supply constraints. However, net income declined 29.4% to $99.7 million due to higher operating expenses. The company issued bullish 2026 revenue guidance of $900–$1,000 million, representing 18–32% growth, and highlighted key upcoming catalysts including a July 2026 PDUFA date for relacorilant in ovarian cancer and data readouts from multiple late-stage trials.